We recently reported significantly improved glucose outcomes without increasing hypoglycemia when using a novel fully closed-loop system (CamAPS HX) with ultrarapid insulin lispro (Lyumjev) compared with insulin pump therapy with a glucose sensor in adults with type 1 diabetes and suboptimal glycemic outcomes (glycated hemoglobin [HbA1c] ≥8.0%).7 This evidence concerns the gene INS and type 1 diabetes mellitus.